TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Relapse-free Survival Time
Endpoint domain: Mortality/survival
Primary endpoint: Change in attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in verbal memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in core symptoms of ASD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Responsiveness Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Positive predictive value of genomic sepsis-test biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of postoperative chronic pain
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in total rTNSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Clinical Fracture Healing of the Tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Radiographic Fracture Healing of the Tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: AHI Change From Baseline at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRP plasma level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quantity of circulating CD14/16 positive monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Screen positive rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American Shoulder and Elbow Surgeons (ASES) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Greater tuberosity bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of peri-operative and post-operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of administration of autologous PBL and/or HSC
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in exercise capacity--peak oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in exercise capacity--heart rate reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in echocardiographic parameters-tissue Doppler imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in echocardiographic parameters-strain and strain rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Expression of endothelial progenitor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Expression of endothelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety in-hospital - Device related
Endpoint domain: Adverse events/effects
Primary endpoint: Safety in-hospital - therapy related
Endpoint domain: Adverse events/effects
Primary endpoint: Safety in-hospital - procedure related
Endpoint domain: Adverse events/effects
Primary endpoint: Safety during treatment period - device related
Endpoint domain: Adverse events/effects
Primary endpoint: Safety during treatment period - procedure related
Endpoint domain: Adverse events/effects
Primary endpoint: Safety during treatment period - therapy related
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients developing endotheliopathies or MODS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with abnormal levels of circulating angiogenic factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with abnormal levels of vascular permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with abnormal levels of inflammatory factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Readmission Within 30-days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total Length of Hospital Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Days on IV Diuretic Therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in post-nasal drip scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with deleterious mutations in the PRDM-16 locus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Genetic outcomes
Primary endpoint: Pharmacokinetics of GSK2251052
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SRSI (summed rest score innervation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SRS (summed rest score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Box Scale-11 (BS-11) Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Body Weight (Percentage [%])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 5% (Yes/No)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events and radiotherapy associated toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of incisional surgical-site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Eosinophil Adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Retinal and Choroidal Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Shannon Diversity of the Preterm Infant Microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clinician assessed depression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported depression symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Myocardial fibrosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of PCPE-1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Train of four ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Number and Percent of Participants with Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: best corrected visual acuity in both eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: kinetic visual field in both eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: central retinal thickness in both eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DERS questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean percent correct score on the OSCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NCDs and NCD risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of days with migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in peak plasma concentration of Doxil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gut permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adverse Events (AE) / Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Strength and range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Language Use Assessed Using Word Count
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Social Belief Updating
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Social Belief Updating- Volatility
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Conditioned Hallucinations
Endpoint domain: Adverse events/effects
Primary endpoint: Occurance of atrial fibrillation episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in Liver function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Family caregiver distress scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Quality of life (QOL) scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mental condition
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Presence of fine particles in fetal lung samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes in PD1 and PD1ligand
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy of 0.1% Triamcinolone in treating Atopic Dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of new diagnosis of CTEPH
Endpoint domain: Mortality/survival
Primary endpoint: Peak Drug Concentration (Cmax) After Single Dose of NAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC) After Single Dose of NAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (t1/2) After Single Dose of NAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Free Walking Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Seated Diastolic Blood Pressure (SeDBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients With Grade 3 or Higher Infusion Related Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of pulmo-pleural fistulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED50 of DEX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemagglutination inhibition (HAI) titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interferon-gamma (IFN-γ) production by T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interferon-gamma (IFN-γ) production by Natural Killer (NK) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in 6-minute Walk Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Borg Dyspnea Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Change in WHO Functional Class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 31P-MRS Redox Ratio (NAD+/NADH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recidivism - Self report of arrests and undetected crimes
Endpoint domain: Mortality/survival
Primary endpoint: Acceptability - number of participants who indicate the module was helpful and number who would recommend treatment to a friend
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of inmates who complete the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of FDG Positive Tampoons
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: forward hepatic venous flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in mean blur rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate cancer detection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in Gingival index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Plaque accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with breast cancer diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Number of women who develop HELLP syndrome
Endpoint domain: Mortality/survival
Primary endpoint: Change in serum level of sFlt-1 and endoglin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Work Productivity Impairment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Total Activity Impairment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Post Booster Polio Neutralizing Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Observation of Mother and Child Interaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Phenotypic measurements of drug metabolism enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of genetic polymorphisms in drug metabolism enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of dose interruptions
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of dose reductions
Endpoint domain: Adverse events/effects
Primary endpoint: Success Rate of Bridge Procera Bridge Zirconia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient global impression of satisfaction (PGIS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of sessions performed using the SaeboGlove
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to early discontinuation of the study drug (doxorubicin)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants with treatment-related serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients who died for SAE
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline VAS pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of tadalafil in men with ED
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multnomah Community Ability Scale (MCAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to Maximal Omeprazole Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Concentration of Omeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve for Omeprazole Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of TCM syndrome index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chromogranin A concentration in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Hemidiaphragmatic paresis (HDP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Symptom responders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUC of ROC curve of maximum increased value of impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Relative Aldosterone Secretion Index (RASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in plasma aldosterone concentration (PAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean change in CGI-BP Severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CGI-BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropathic Pain Symptom Inventory (NPSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-Injurious Behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from death and cardiac transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Ampulla of Vater detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between two capsule examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute mountain sickness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-rater reproducibility concerning displacement of the humeral head on the frontal plane
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Inter-rater reproducibility concerning displacement of the humeral head on the sagittal plane
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Inter-rater reproducibility concerning humeral head split
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Inter-rater reproducibility concerning calcar comminution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Inter-rater reproducibility concerning medial hinge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: eGFR (CKD-EPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Favorable Clinical Response Assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease the degrees of toxicities of Radiotherapy and Chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Improve the quality of life of patients during radiotherapy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in appropriateness of anticholinergic medication prescribing practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Vaso-Occlusive Crises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: epithelial cell proliferation in breast tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: immediate postoperative analgesic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician-rated Depression Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-rated Depression Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of Autosomal Dominant Polycystic Kidney Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Vertigo Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Vertigo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in locomotor function, mobility and balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI of the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vaccine-associated adverse events (AEs) or serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of bronchial obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in serum creatinine levels at 24h after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: thyroid function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Receptor gene rearrangement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time 0 extrapolated to infinity [AUC(INF)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from time 0 up to time T [AUC(0-T)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Serious and Non-serious TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Effective Dose 50% (ED50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect Maximum (Emax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monthly attack frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial appearance changes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complete retinal reattach rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Fugl Meyer Assessment-Upper Limb (FMA-UL) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes